Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery

Circulation Journal

Volumn 69, Issue 10, 2005, Pages 1256-1259

  Iida, Osamu ^a   Nanto, Shinsuke ^a   Uematsu, Masaaki ^a   Morozumi, Takakazu ^a   Kotani, Jun Ichi ^a   Awata, Masaki ^a   Onishi, Toshinari ^a   Ito, Noriaki ^a   Oshima, Fusako ^a   Minamiguchi, Hitoshi ^a   Kitakaze, Masafumi ^b   Nagata, Seiki ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cilostazol; Femoropopliteal artery; Percutaneous transluminal angioplasty; Restenosis; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIMAPROST; SARPOGRELATE; TICLOPIDINE; WARFARIN;

AGED; ANGIOGRAPHY; ARTERY DIAMETER; ARTERY OCCLUSION; ARTICLE; DRUG ACTIVITY; FEMALE; FEMORAL ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPLITEAL ARTERY; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVASCULARIZATION; SYMPTOM;

AGED; ANGIOPLASTY, BALLOON; CELL PROLIFERATION; FEMALE; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MYOCYTES, SMOOTH MUSCLE; PLATELET AGGREGATION INHIBITORS; STENTS; TETRAZOLES;

EID: 25644457532     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1256     Document Type: Article

References (39)

1. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long segment superficial fem oral artery disease after suboptimal angioplasty. J Vasc Surg 1997; 25: 74-83.
2. Conoroy RM, Gordon IL, Tobis JM, Hiro T, Kasaoka S, Stemmer EA, et al. Angioplasty and stent placement in chronic occlusion of the superficial femoral artery: Technique and results. J Vasc Interv Radiol 2000; 11: 1009-1020.
3. Gordon IL, Conroy RM, Arefi M, Tobis JM, Stemmer EA, Wilson SE. Three-year outcome of endovascular treatment of superficial femoral artery occlusion. Arch Surg 2001; 136: 221-228.
4. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002; 13: 257-266.
5. Wolosker N, Nakano L, Anacleto MM, Puech-Leao P. Primary utilization of stents in angioplasty of superficial femoral artery. Vasc Endovascular Surg 2003; 37: 271-277.
6. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1998; 36: 313-320.
7. Kawamura K, Watanabe K, Kimura Y. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung 1985; 35: 1149-1154.
8. Shintani S, Watanabe K, Kawamura K, Mori T, Tani T, Toba Y, et al. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs. Arzneimittelforschung 1985; 35: 1163-1172.
9. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung 1985; 35: 1203-1208.
10. Kobayashi S, Yamaguchi S, Katsube T, Kitani M, Okada K, Tsunematsu T. Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. Arzneimittelforschung 1985; 35: 1193-1197.
11. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, et al. Effect of cilostazol, cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Phamacol 1992; 20: 900-906.
12. Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, Togo M, et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1999; 142: 41-46.
13. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation 1998; 98: 678-686.
14. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999; 27: 159: 2041-2050.
15. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-274; discussion 274-275.
16. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530.
17. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group: TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1- S296.
18. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation1999; 100: 21-26.
19. Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, et al. Effect of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499-503.
20. Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, et al. Effects of cilostazol on lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J 2001; 141: 124-130.
21. Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, et al. Randomized comparison of cilostazol vs ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late loss. Am Heart J 2002; 144: 303-308.
22. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J 1998; 135: 495-502.
23. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998; 82: 144-147.
24. Douglas JS, Weintraub WS, Holmes D. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. Clin Cardiol 2003; 10: 451-454.
25. Weintraub WS, Foster J, Culler SD, Becker ER, Parker K, Zhang Z, et al. Cilostazol for RESTenosis trial: Methods for the economic and quality of life supplement to the Cilostazol for RESTenosis (CREST) trial. J Invasive Cardiol 2004; 16: 257-259.
26. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Invest Radiol 1995; 30: 532-537.
27. Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K, Kurabayashi M. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: A randomized comparison of ticlopidine and cilostazol. Circ J 2004; 68: 610-614.
28. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59: 347-356.
29. Umekawa H, Tanaka T, Kimura Y, Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 1984; 33: 3339-3344.
30. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144-1149.
31. Morishita R, Higaki J, Hayashi SI, Yo Y, Aoki M, Nakamura S, et al. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia 1997; 40: 1053-1061.
32. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001; 44: 1034-1042.
33. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis 2001; 158: 121-128.
34. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 1997; 29: 491-495.
35. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide- induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300: 709-715.
36. Hashimoto A, Hirose Y, Miyakoda G, Mori T. Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, possesses protective effect on endothelium. Atherosclerosis Suppl 2003; 4(2: 76).
37. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectinlike oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol. Circulation 2004; 109: 1022-1028.
38. Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I. Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb 2003; 10: 93-98.
39. Matsui K, Yoshioka T, Murakami Y, Takahashi M, Shimada K, Ikeda U. Serum concentrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease. Circ J 2003; 67: 660-662.